Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rebecca Powell

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
The Lancet. Infectious Diseases|November 28, 2023
Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trialAnne Wajja, Beatrice Nassanga, Agnes Natukunda, et al.
The Lancet. Infectious Diseases|January 6, 2024
Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis controlAnne Wajja, Beatrice Nassanga, Agnes Natukunda, et al.
Vaccines|April 30, 2021
Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy <i>M.tb</i>-Infected AdultsMichael Riste, Julia L Marshall, Iman Satti, et al.
Journal of Virology|March 8, 2013
Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopesSimon Hoffenberg, Rebecca Powell, Alexei Carpov, et al.
Nature Communications|May 29, 2025
Early mucosal responses following a randomised controlled human inhaled infection with attenuated Mycobacterium bovis BCGJulia L Marshall, Iman Satti, Mirvat Surakhy, et al.
The Lancet. Infectious Diseases|April 15, 2024
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trialIman Satti, Julia L Marshall, Stephanie A Harris, et al.
The Lancet. Microbe|May 4, 2024
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection studySusan Jackson, Julia L Marshall, Andrew Mawer, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
The Lancet. Infectious Diseases|November 28, 2023
Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trialAnne Wajja, Beatrice Nassanga, Agnes Natukunda, et al.
The Lancet. Infectious Diseases|January 6, 2024
Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis controlAnne Wajja, Beatrice Nassanga, Agnes Natukunda, et al.
Vaccines|April 30, 2021
Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy <i>M.tb</i>-Infected AdultsMichael Riste, Julia L Marshall, Iman Satti, et al.
Journal of Virology|March 8, 2013
Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopesSimon Hoffenberg, Rebecca Powell, Alexei Carpov, et al.
Nature Communications|May 29, 2025
Early mucosal responses following a randomised controlled human inhaled infection with attenuated Mycobacterium bovis BCGJulia L Marshall, Iman Satti, Mirvat Surakhy, et al.
The Lancet. Infectious Diseases|April 15, 2024
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trialIman Satti, Julia L Marshall, Stephanie A Harris, et al.
The Lancet. Microbe|May 4, 2024
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection studySusan Jackson, Julia L Marshall, Andrew Mawer, et al.
Pageof 5